Myeloproliferative neoplasms (MPNs) such as polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF), are frequently associated with the somatic V617F mutation in the pseudo kinase domain of JAK2 [1–4]. This evidence concerns the gene JAK2 and acquired polycythemia vera.